 | | Vol. 12.47 – 10 December, 2021 |
| |
|
|
| Investigators validated the therapeutic efficacy of the FDA-approved FGFR inhibitor pemigatinib, in an integrated platform consisting of human and murine prostate cancer (PCa) cells, and the transgenic multistage TRAMP model of PCa that recapitulated both androgen-dependent and CRPC settings.
[Cancer Letters] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers suggested that circSERPINA3 regulated apoptosis, autophagy and aerobic glycolysis of prostate cancer cells by competitively binding to miR-653-5p and recruiting BUD13.
[Journal of Translational Medicine] |
|
|
|
| The authors elucidated the function of androgen receptor (AR) in prostate cancer (PCa) and suggested that AR positively regulated eIF5A2 expression in androgen-dependent cells, and stimulation of AR expression and signaling in prostate tumors promoted PCa metastasis.
[Cell Death Discovery] |
|
|
|
| Scientists discovered an exosomal lncRNA HOXD-AS1 was upregulated in CRPC cell line derived exosomes and serum exosomes from metastatic prostate cancer patients, which correlated with its tissue expression.
[Cell Death Discovery] |
|
|
|
| Elevated expression of lysine demethylase 6A (KDM6A) and 6B (KDM6B) has been reported in prostate cancer (PCa). Researchers reported novel KDM6A/B downstream targets involved in controlling PCa cell proliferation.
[Molecular Pharmacology] |
|
|
|
| The authors investigated a combination therapy of novel androgen receptor (AR) antagonists and statin, simvastatin, for CRPC and found that a combination of novel AR antagonists and simvastatin could potentially affect CRPC growth through both androgen-dependent and androgen-independent mechanisms.
[Prostate] |
|
|
|
| Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of prostate cancer (PCa). However, 99% of PCa patients will develop resistance to docetaxel within three years. Investigators identified a shared transcription factor activity network that drove docetaxel resistance in PCa.
[BMC Cancer] |
|
|
|
| CCK-8, colony formation, transwell, tube formation and flow cytometry assays were applied to assess cell proliferation, motility, angiogenesis, cell cycle distribution and apoptosis.
[andrology] |
|
|
|
| The authors explored the expression level of miR-214-5p in prostate cancer and made a preliminary study of its molecular mechanism in the development of prostate cancer to provide effective new strategies for the treatment of prostate cancer.
[Journal of Surgical Oncology] |
|
|
|
| Scientists aimed to improve the sensitivity and efficacy of chemotherapeutic drugs through the inhibition of autophagy. They suggested that the amphiphilic peptide micelle systems developed had the potential to combine autophagy inhibition and chemotherapy in cancer treatment, especially for prostate cancer.
[Journal of Biomaterials Applications] |
|
|
|
|
| Investigators summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.
[Personalized Medicine] |
|
|
|
| A new breakthrough development in cancer treatment is chimeric antigen receptor (CAR)-T cell therapy. The authors focus on its efficacy & safety in prostate cancer, obstacles impeding its clinical use, and some strategies trying to overcome them.
[Biomarkers] |
|
|
|
|
| SynDevRx, Inc. announced a research collaboration with Australia’s Queensland University of Technology. The collaboration with Professor Colleen Nelson, PhD, and her team will study the role of methionine aminopeptidase 2 inhibition in tumor growth in castration resistant and other treatment resistant forms of prostate cancer.
[SynDevRx, Inc. (Businesswire, Inc.)] |
|
|
|
|
| January 16 – 20, 2022
Banff, Alberta, Canada |
|
|
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | University of California Irvine – Irvine, California, United States |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
| | The University of Chicago – Chicago, Illinois, United States |
|
|
|
| | University of Freiburg – Freiburg, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
